Identification
Instrument name
IMMUPHARMA
Symbol
ALIMM
ISIN code
GB0033711010
LEI code
213800VZKGHXC7VUS895
Exchange / Market
Euronext Growth
Trading location
Brussels
Products family
Stocks
ICB
Biotechnology
Website address
Operation
IPO date
IPO type
Direct listing

Company profile

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, LupuzorTM, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for LupuzorTM to fund a new international Phase III trial for LupuzorTM and commercialise in the United States.

Source: Cofisem - Last Update: 18 Nov 2020
Key Executives
Chief Executive Officer Dimitri Dimitriou
Investor Relations Director Lisa Baderoon
Chief Operations Officer Franklin Tim
Chief Scientific Officer Robert Zimmer
Source: Cofisem - Last Update: 18 Nov 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales 87 91 175 224 97
Income from ordinary activities 87 91 175 224 97
Operating income -6,976 -9,102 -8,447 -8,941 -5,832
Cost of financial indebtedness net -514 8 -4 13
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income -6,799 -8,118 -7,267 -7,225 -4,980
Net income (Group share) -6,799 -8,118 -7,267 -7,225 -4,980
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit GBP - thousands GBP - thousands GBP - thousands GBP - thousands GBP - thousands
Account Standards
Source: Cofisem - Last Update: 18 Nov 2020
Shareholder information
Robert Zimmer 11.10 %
Lanstead Capital Investors LP 10.81 %
Source: Cofisem - Last Update: 18 Nov 2020